The global market for CAR T-cell therapy is expected to grow from $4.6 billion in 2024 and projected to reach $25.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 40.2% from 2024 to 2029.
CAR T-cell therapy holds a huge potential benefit, due to its being tailored to each patient’s needs. To target and eliminate cancer cells, T cells are extracted from the patient, genetically altered in the lab to produce CARs on their surface and reintroduced into the patient. CAR T-cell-based treatments have attracted much interest in solid tumors because of their remarkable effectiveness in hematological malignancies. There are now six autologous CAR T-cell treatments that have received FDA approval and are used to treat different types of blood cancer in the U.S. CAR T-cell treatments are being studied in 1,439 clinical studies worldwide in addition to these commercially available products.
CAR T-cell therapy holds a huge potential benefit, due to its being tailored to each patient’s needs. To target and eliminate cancer cells, T cells are extracted from the patient, genetically altered in the lab to produce CARs on their surface and reintroduced into the patient. CAR T-cell-based treatments have attracted much interest in solid tumors because of their remarkable effectiveness in hematological malignancies. There are now six autologous CAR T-cell treatments that have received FDA approval and are used to treat different types of blood cancer in the U.S. CAR T-cell treatments are being studied in 1,439 clinical studies worldwide in addition to these commercially available products.
Report Scope
This report incorporates an in-depth analysis of CAR T-cell therapy’s current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players’ profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies’ business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.The report includes:
- 14 data tables and 71 additional tables
- Overview and analysis of the global markets for chimeric antigen receptor (CAR) T-cell therapy with an emphasis on the current status of R&D
- Analyses of global market trends, with revenue data for 2022 and 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects for the global CAR T-cell therapy market, along with a market share analysis by product, application, technology type and region
- Facts and figures pertaining to the market dynamics, technological advances, product innovations, regulatory landscape, clinical trials, research and business consolidations, and the impact of macroeconomic factors
- Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
- Assessment of current marketed drugs, including drug development activity, R&D activity and anticipated developments, along with a look into the patent expirations in the industry
- An analysis of patents, emerging trends and developments in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Novartis AG, Bristol Myers Squibb Co., Gilead Sciences Inc., Johnson & Johnson Services Inc., and AstraZeneca
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Emerging Technologies and Clinical Trials
Chapter 5 Market Segmentation Analysis
Chapter 6 Patent Review and New Developments
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in the CAR T-Cell Therapy Market: ESG Perspective
Chapter 9 Appendix
List of Tables
List of Figures
Companies Mentioned
- AbbVie Inc.
- Allogene Therapeutics
- Amgen Inc.
- AstraZeneca
- Bluebird Bio Inc.
- Bristol-Myers Squibb Co.
- Cellectis SA
- Eureka Therapeutics Inc.
- Gilead Sciences Inc.
- Icell Gene Therapeutics Inc.
- Johnson & Johnson Services Inc.
- Les Laboratoires Servier
- Novartis AG
- Pfizer Inc.
- Protheragen Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | March 2025 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value ( USD | $ 4.6 Billion |
| Forecasted Market Value ( USD | $ 25.1 Billion |
| Compound Annual Growth Rate | 40.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
